APDN Stock Overview
A biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Applied DNA Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.16 |
| 52 Week High | US$22.80 |
| 52 Week Low | US$0.15 |
| Beta | 0.45 |
| 11 Month Change | -48.35% |
| 3 Month Change | -93.31% |
| 1 Year Change | -99.09% |
| 33 Year Change | -99.87% |
| 5 Year Change | -99.81% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
The Market Doesn't Like What It Sees From Applied DNA Sciences, Inc.'s (NASDAQ:APDN) Revenues Yet As Shares Tumble 26%
Dec 20
Is Applied DNA Sciences (NASDAQ:APDN) In A Good Position To Invest In Growth?
Jan 01Applied DNA climbs 51% after winning large purchase order
Oct 10Applied DNA stock rises 12% on launching monkeypox testing service in New York
Sep 06Applied DNA adds 17% as company seeks approval for monkeypox test in New York
Aug 19Upgrade: Analysts Just Made A Notable Increase To Their Applied DNA Sciences, Inc. (NASDAQ:APDN) Forecasts
Aug 17Applied DNA Sciences gains as it secures ~$3.6M proceeds from warrant exercise
Aug 09Shareholder Returns
| APDN | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -5.7% | 5.3% | 2.2% |
| 1Y | -99.1% | 4.8% | 32.6% |
Return vs Industry: APDN underperformed the US Life Sciences industry which returned 2.9% over the past year.
Return vs Market: APDN underperformed the US Market which returned 31.6% over the past year.
Price Volatility
| APDN volatility | |
|---|---|
| APDN Average Weekly Movement | 24.5% |
| Life Sciences Industry Average Movement | 8.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: APDN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: APDN's weekly volatility has decreased from 31% to 24% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 54 | James Hayward | www.adnas.com |
Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-based therapeutics.
Applied DNA Sciences, Inc. Fundamentals Summary
| APDN fundamental statistics | |
|---|---|
| Market cap | US$7.82m |
| Earnings (TTM) | -US$7.52m |
| Revenue (TTM) | US$3.40m |
2.4x
P/S Ratio-1.1x
P/E RatioIs APDN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APDN income statement (TTM) | |
|---|---|
| Revenue | US$3.40m |
| Cost of Revenue | US$2.55m |
| Gross Profit | US$850.98k |
| Other Expenses | US$8.37m |
| Earnings | -US$7.52m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.15 |
| Gross Margin | 25.04% |
| Net Profit Margin | -221.34% |
| Debt/Equity Ratio | 0% |
How did APDN perform over the long term?
See historical performance and comparison